Search

Your search keyword '"Pestronk, A"' showing total 921 results

Search Constraints

Start Over You searched for: Author "Pestronk, A" Remove constraint Author: "Pestronk, A" Topic business Remove constraint Topic: business
921 results on '"Pestronk, A"'

Search Results

1. FTC's noncompete rule is effectively dead

2. FTC rule excludes franchise agreements

3. Understanding terms in MSAs

4. Old host refuses to transfer bookings

5. Figuring out the right earnout formula

6. Can contracts curb social media posts?

7. The do's and don'ts of selling travel insurance

8. 5 things to know when buying an agency

9. Getting help with debit memos

10. Contracts to consider in agency purchases

11. Six tips for getting the best GDS deal

12. How not to be the 'merchant of record'

13. Defining terms in DOT'S airline refunds rule

14. Who will inherit your business?

15. Noncompetes are about to become illegal

16. The DOT has deputized state AGs

17. Is the DOT's refund rule still 'anti-agent'?

18. Client's DUI could keep him out of Canada

19. How to get rid of an IC

20. Amex GBT-CWT linkup is full of upside

21. Affiliating to meet AA's NDC requirement

22. Little legal recourse against AA's moves

23. Class action against airlines won't fly

24. The growing trend of verticalization

25. The legality of IC exclusivity

26. Why GDS contracts are full of dangers

27. Green flags in host agency contracts

28. Red flags in host agency contracts

29. More questions about selling an agency

30. A travel person's guide to selling an agency

31. There's no testing option for vaccine mandate

32. Keeping contracts up with the times

33. Inside Illinois' consumer-protection law

34. The key to working with DMCs

35. Selling adventure? Have a disclaimer

36. What employees, ICs can bring to your agency

37. Is there a duty to warn about Israel travel?

38. Steps to follow for a valid trust account

39. You likely need to have a privacy policy

40. No need to disclose markups to clients

41. Your duty to a client has its limits

42. Answers for a new advisor

43. What's negotiable for ICs? It depends

44. The bright side of long-term GDS contracts

45. ASTA's consumer-driven case against AA

46. NDC is wanting, but there's no avoiding it

47. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial

48. Whose booking is it anyway?

49. Five elements to required disclosures

50. The big pro to errors and omissions coverage

Catalog

Books, media, physical & digital resources